Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA ...

14 November 2026 · By · Wire by Fusion42

Published

14 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

Servier presented updated four-year Phase 2 FIREFLY-1 study results showing prolonged treatment-free intervals and consistent safety profile for OJEMDA (tovorafenib) in pediatric low-grade glioma patients with BRAF alterations.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can leverage OJEMDA’s durable off-treatment periods to design patient care that reduces therapy burden while maintaining tumour control. Treatment decisions in pediatric low-grade glioma now gain clarity with more evidence on long-term outcomes.

◆ Coverage

1 source · 14 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpediatric-oncologyclinical-trialsbraf-inhibitorbiotechgliomadrug-safety